The first FDA-approved targeted treatment for ROS1-positive NSCLC was crizotinib [25]; G2032R is the most common drug resistance mutation and has clinically responded to ROS1/TRK/ALK inhibitors such as repotrectinib and taletrectinib [25]. Here, NTRK1 is linked to non-small cell lung carcinoma.